Friday, July 10, 2026
🇺🇸 FDA

pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma

Janssen-Cilag International N.V

Janssen-Cilag International N.V.

Janssen-Cilag International N.V clinical programs — 39 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
161
Drugs
159
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Janssen-Cilag International N.V projects

39 ClinicalTrials.gov programs sponsored by Janssen-Cilag International N.V.

Janssen-Cilag International N.V has 39 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

39 programs

Clinical programs

  1. 17000139BLC2001

    Janssen-Cilag International N.V.

    Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder

    phase 2 small molecule active

    1 trial

  2. 17000139BLC2002

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma of the Bladder

    phase 2 small molecule active

    1 trial

  3. 42756493BLC2001

    Janssen-Cilag International N.V.

    Urothelial cancer

    phase 2 small molecule active

    1 trial

  4. 42756493BLC2002

    Janssen-Cilag International N.V.

    Metastatic or Locally Advanced Urothelial Cancer

    phase 2 small molecule active

    1 trial

  5. 42756493BLC2003

    Janssen-Cilag International N.V.

    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions

    phase 2 small molecule active

    1 trial

  6. 42756493CAN2002

    Janssen-Cilag International N.V.

    Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

    phase 2 small molecule active

    1 trial

  7. 54179060CLL2032

    Janssen-Cilag International N.V.

    Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  8. 54179060MCL3004

    Janssen-Cilag International N.V.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  9. 54767414AMY2009

    Janssen-Cilag International N.V.

    Amyloid Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  10. 54767414MMY2093

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 other active

    1 trial

  11. 61186372GIC2002

    Janssen-Cilag International N.V.

    Advanced or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  12. 61186372HNC2002

    Janssen-Cilag International N.V.

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  13. 61186372NSC2002

    Janssen-Cilag International N.V.

    Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  14. 61186372NSC2005

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. 61186372NSC2007

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. 61186372PANSC2001

    Janssen-Cilag International N.V.

    Unresectable Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. 61186372PANSC2002

    Janssen-Cilag International N.V.

    Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. 64007957MMY1001

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  19. 64007957MMY1003

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  20. 64007957MMY3001

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  21. 64042056ALZ2001

    Janssen-Cilag International N.V.

    Preclinical Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  22. 64407564MMY1001

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  23. 64407564MMY2006

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 2 small molecule active

    1 trial

  24. 68284528MMY2012

    Janssen-Cilag International N.V.

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  25. 77242113UCO2001

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  26. 78934804CRD2001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  27. 78934804UCO2001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  28. 80202135CDP3001

    Janssen-Cilag International N.V.

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  29. 80202135IIM2001

    Janssen-Cilag International N.V.

    Active Idiopathic Inflammatory Myopathies (IIM)

    phase 2 small molecule active

    1 trial

  30. 81201887MDG3002

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  31. 88545223PSA2001

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  32. 95475939ADM2001

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  33. JNJ-54767414 for Multiple Myeloma

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  34. JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  35. JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  36. JNJ-81241459 for Plaque Psoriasis

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  37. Placebo for JNJ-95597528, JNJ-95597528

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  38. TENOFOVIR ALAFENAMIDE for Hepatitis B and Hepatitis D Viral Co-infection

    Janssen-Cilag International N.V.

    Hepatitis B and Hepatitis D Viral Co-infection

    phase 2 small molecule active

    1 trial

  39. cetrelimab, JNJ-63723283

    Janssen-Cilag International N.V.

    Advanced Stage Solid Tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Janssen-Cilag International N.V have?

39 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.